← Back to Home

Near-Total Mast Cell Depletion, but No Improvement in Itch: Celldex Ends Prurigo Nodularis Program

Barzolvolimab markedly suppressed mast cell markers in a Phase 2 trial but failed to improve itch or skin nodules; the setback not only ends development in one indication but also raises concerns about the disease mechanism.

By SURL BioNews

A drug can precisely hit its intended biological target without necessarily making patients better. Celldex Therapeutics’ anti-KIT antibody barzolvolimab substantially reduced serum tryptase in a Phase 2 trial in prurigo nodularis, indicating strong systemic mast cell suppression. However, patients’ itch and skin lesions were no better than with placebo. The company has therefore ended development for this indication.

The randomized, double-blind, placebo-controlled trial, registered as NCT06366750, enrolled 140 adults with moderate-to-severe prurigo nodularis. Participants first received a 450 mg loading dose, followed by subcutaneous injections of 150 or 300 mg of barzolvolimab every four weeks, or placebo. The double-blind treatment period lasted 24 weeks, followed by an additional 16 weeks of follow-up.

The primary endpoint was assessed at Week 12: patients had to achieve at least a 4-point improvement from baseline on the Worst Itch Numeric Rating Scale. Neither dose separated from placebo, and key secondary endpoints, including investigator-assessed clearance of skin nodules, were also not met. Extending treatment to Week 24 still showed no improvement in efficacy.

Barzolvolimab binds to the KIT receptor on the surface of mast cells, blocking the signaling required to maintain the survival and function of these immune cells. In the trial, serum tryptase declined rapidly and remained suppressed, supporting that the drug produced its intended biological effect. However, the disconnect between the biomarker and clinical symptoms suggests that mast cells may not be the primary disease-driving factor in prurigo nodularis, or at least that depleting mast cells alone is insufficient to reverse this complex disease.

Safety was not the primary reason for ending the program. Celldex said overall tolerability, including with the new 450 mg loading dose, was consistent with previous studies, with no new safety signals observed. Following the announcement, the company’s shares fell in after-hours trading; different reports put the decline at approximately 5% to more than 7%. Targeted therapies including dupilumab and nemolizumab are already approved for prurigo nodularis, and later entrants also face a higher efficacy bar.

These results do not mean the end of the overall barzolvolimab program. Celldex is continuing studies in chronic spontaneous urticaria, cold urticaria, symptomatic dermographism, and atopic dermatitis. Phase 3 topline data in chronic spontaneous urticaria are expected in September or October 2026, while Phase 2 results in atopic dermatitis are scheduled to follow later. However, the available information consists only of topline results, with complete efficacy figures for each group, statistical analyses, and detailed adverse-event data still unavailable. The precise role of mast cells in prurigo nodularis therefore cannot be fully determined from a single failed trial.

References

  1. Celldex Therapeutics
  2. ClinicalTrials.gov
  3. Thomson Reuters